Back to Multiple Sclerosis
NCT04676555
NCT04676555
Who may be able to join
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with a form of multiple sclerosis called relapsing MS (this includes clinically isolated syndrome/CIS, relapsing-remitting MS/RRMS, or active secondary progressive MS/aSPMS), confirmed using standard diagnostic guidelines from 2017
- You have already been prescribed either Ocrelizumab or Ofatumumab to treat your MS as part of your normal care — and this prescription was made before being invited to join this study
- You are able to read and write in English
- You are willing and able to give your consent to take part in the study
Who may not be able to join:
- You are currently taking part in any other clinical trial for relapsing multiple sclerosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
Novartis Pharmaceuticals
Registry
clinicaltrials_gov
Start date
11 May 2021
Est. completion
21 October 2021
Where this trial is recruiting
🇦🇺 Australia
🇺🇸 United States
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Time spent by Healthcare Providers (staff) in the preparation, administration and post-treatment observation of Ocrelizumab and Ofatumumab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.